Effects of physiologic levels of glucagon and growth hormone on human carbohydrate and lipid metabolism. Studies involving administration of exogenous hormone during suppression of endogenous hormone secretion with somatostatin.

To study the individual effects of glucagon and growth hormone on human carbohydrate and lipid metabolism, endogenous secretion of both hormones was simultaneously suppressed with somatostatin and physiologic circulating levels of one or the other hormone were reproduced by exogenous infusion. The interaction of these hormones with insulin was evaluated by performing these studies in juvenile-onset, insulin-deficient diabetic subjects both during infusion of insulin and after its withdrawal. Infusion of glucagon (1 ng/kg-min) during suppression of its endogenous secretion with somatostatin produced circulating hormone levels of approximately 200 pg/ml. When glucagon was infused along with insulin, plasma glucose levels rose from 94 +/- 8 to 126 +/- 12 mg/100 ml over 1 h (P less than 0.01); growth hormone, beta-hydroxy-butyrate, alanine, FFA, and glycerol levels did not change. When insulin was withdrawn, plasma glucose, beta-hydroxybutyrate, FFA, and glycerol all rose to higher levels (P less than 0.01) than those observed under similar conditions when somatostatin alone had been infused to suppress glucagon secretion. Thus, under appropriate conditions, physiologic levels of glucagon can stimulate lipolysis and cause hyperketonemia and hyperglycemia in man; insulin antagonizes the lipolytic and ketogenic effects of glucagon more effectively than the hyperglycemic effect. Infusion of growth hormone (1 mug/kg-h) during suppression of its endogenous secretion with somastostatin produced circulating hormone levels of approximately 6 ng/ml. When growth hormone was administered along with insulin, no effects were observed. After insulin was withdrawn, plasma beta-hydroxybutyrate, glycerol, and FFA all rose to higher levels (P less than 0.01) than those observed during infusion of somatostatin alone when growth hormone secretion was suppressed; no difference in plasma glucose, alanine, and glucagon levels was evident. Thus, under appropriate conditions, physiologic levels of growth hormone can augment lipolysis and ketonemia in man, but these actions are ordinarily not apparent in the presence of physiologic levels of insulin.

[1]  N. Altszuler,et al.  Interaction of Somatostatin, Glucagon, and Insulin on Hepatic Glucose Output in the Normal Dog , 1976, Diabetes.

[2]  L. Orci,et al.  Identification of glucagon in the gastrointestinal tract. , 1975, The Journal of clinical investigation.

[3]  J. McGarry,et al.  Hormonal control of ketogenesis. Rapid activation of hepatic ketogenic capacity in fed rats by anti-insulin serum and glucagon. , 1975, The Journal of clinical investigation.

[4]  E. Tsalikian,et al.  Prevention of human diabetic ketoacidosis by somatostatin. Evidence for an essential role of glucagon. , 1975, The New England journal of medicine.

[5]  D. Schade,et al.  Modulation of Fatty Acid Metabolism by Glucagon in Man: II. Effects in Insulin-deficient Diabetics , 1975, Diabetes.

[6]  C. J. Goodner,et al.  Somatostatin blockade of acute and chronic stimuli of the endocrine pancreas and the consequences of this blockade on glucose homeostasis. , 1975, The Journal of clinical investigation.

[7]  E. Tsalikian,et al.  Plasma glucagon and alanine responses to acute insulin deficiency in man. , 1975, The Journal of clinical endocrinology and metabolism.

[8]  L. Orci,et al.  Glucagon: role in the hyperglycemia of diabetes mellitus. , 1975, Science.

[9]  R. Guillemin,et al.  Evidence for a physiologic role of pancreatic glucagon in human glucose homeostasis: studies with somatostatin. , 1975, Metabolism: clinical and experimental.

[10]  L. Orci,et al.  THE ESSENTIAL ROLE OF GLUCAGON IN THE PATHOGENESIS OF DIABETES MELLITUS , 1975, The Lancet.

[11]  D. Kipnis,et al.  Physiologic Mechanisms in the Development of Starvation Ketosis in Man , 1975, Diabetes.

[12]  M. Lorenzi,et al.  Effect of somatostatin on plasma glucose and insulin responses to glucagon and tolbutamide in man. , 1974, The Journal of clinical endocrinology and metabolism.

[13]  R. Guillemin,et al.  Inhibition of Pancreatic Glucagon Responses to Arginine by Somatostatin in Normal Man and in Insulin-Dependent Diabetics , 1974, Diabetes.

[14]  M. Vranic,et al.  Increased “Glucagon Immunoreactivity” in Plasma of Totally Depancreatized Dogs , 1974, Diabetes.

[15]  A. Kastin,et al.  Glucagon control of fasting glucose in man. , 1974, Lancet.

[16]  P. Foà,et al.  Plasma Glucose, Insulin, Pancreatic, and Enteroglucagon Levels in Normal and Depancreatized Dogs 1 , 1974, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[17]  J. Kinney,et al.  Concentrations of Glucagon and the Insulin: Glucagon Ratio in the Portal and Peripheral Circulation 1 , 1974, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[18]  R. Guillemin,et al.  Effects of somatostatin on plasma glucose and glucagon levels in human diabetes mellitus. Pathophysiologic and therapeutic implications. , 1974, The New England journal of medicine.

[19]  S. Fineberg,et al.  Acute Metabolic Effects of Human Growth Hormone , 1974, Diabetes.

[20]  S. Yen,et al.  Effect of somatostatin in patients with acromegaly: suppression of growth hormone, prolactin, insulin and glucose levels. , 1974, The New England journal of medicine.

[21]  C. H. Mortimer,et al.  Effects of growth-hormone release-inhibiting hormone on circulating glucagon, insulin, and growth hormone in normal, diabetic, acromegalic, and hypopituitary patients. , 1974, Lancet.

[22]  W. Blackard,et al.  Portal and Peripheral Vein Immunoreactive Glucagon Concentrations After Arginine or Glucose Infusions , 1974, Diabetes.

[23]  K. Alberti,et al.  Inhibition of insulin secretion by somatostatin. , 1973, Lancet.

[24]  L. Nilsson.  Liver glycogen content in man in the postabsorptive state. , 1973, Scandinavian journal of clinical and laboratory investigation.

[25]  A. P. Hansen,et al.  Some Actions of Growth Hormone Release Inhibiting Factor , 1973, British medical journal.

[26]  T. Merimee,et al.  A survey of growth hormone secretion and action. , 1973, Metabolism: Clinical and Experimental.

[27]  P. Felig.  The glucose-alanine cycle. , 1973, Metabolism: clinical and experimental.

[28]  R. Scow,et al.  Role of Lipolytic and Glucocorticoid Hormones in the Development of Diabetic Ketosis , 1972, Diabetes.

[29]  M. Mitchell,et al.  Effect of propranolol on the response of serum growth hormone to glucagon. , 1971, The Journal of clinical endocrinology and metabolism.

[30]  P. Felig,et al.  Glucose and lipid homeostasis in the absence of human growth hormone. , 1971, The Journal of clinical investigation.

[31]  C. Migeon,et al.  Determination of integrated plasma concentrations and true secretion rates of human growth hormone. , 1971, The Journal of clinical endocrinology and metabolism.

[32]  P. Felig,et al.  Metabolic response to human growth hormone during prolonged starvation. , 1971, The Journal of clinical investigation.

[33]  R. Unger,et al.  Glucagon levels and metabolic effects in fasting man. , 1970, The Journal of clinical investigation.

[34]  N. Kalant,et al.  Effects of insulin and growth hormone on the flux rates of plasma glucose and plasma free fatty acids in man. , 1970, The Journal of clinical endocrinology and metabolism.

[35]  J. Earll,et al.  Remarkable Sensitivity to Insulin in a Patient with Hypopituitarism and Diabetic Acidosis , 1968, Diabetes.

[36]  L. Frohman,et al.  Acute effects of human growth hormone on insulin secretion and glucose utilization in normal and growth hormone deficient subjects. , 1967, The Journal of clinical endocrinology and metabolism.

[37]  V. Marks,et al.  Interrelationship of Glucagon, Insulin and Glucose: The Insulinogenic Effect of Glucagon , 1966, Diabetes.

[38]  J. Penhos,et al.  The effect of growth hormone on the metabolism of lipids and on urea formation by the perfused rat liver. , 1966, Metabolism: clinical and experimental.

[39]  R. Scow,et al.  Effect of growth hormone and dexamethasone on lipolysis and metabolism in isolated fat cells of the rat. , 1965, The Journal of biological chemistry.

[40]  E. Knoblock,et al.  Elevation of plasma epinephrine levels produced by glucagon in vivo. , 1963, Endocrinology.

[41]  C. Ezrin,et al.  Metabolic effects of glucagon in human subjects. , 1960, Metabolism: clinical and experimental.

[42]  R. Eaton,et al.  Modulation of fatty acid metabolism by glucagon in man. I. Effects in normal subjects. , 1975, Diabetes.

[43]  S. B. Lewis,et al.  Effects of glucagon on lipolysis and ketogenesis in normal and diabetic men. , 1974, The Journal of clinical investigation.

[44]  W. A. Müller,et al.  Hyperglucagonemia in diabetic ketoacidosis. Its prevalence and significance. , 1973, The American journal of medicine.

[45]  K. Zierler,et al.  EFFECT OF HUMAN GROWTH HORMONE ON MUSCLE AND ADIPOSE TISSUE METABOLISM IN THE FOREARM OF MAN. , 1965, The Journal of clinical investigation.

[46]  M. Bogdonoff,et al.  Alterations in Free Fatty Acid Metabolism in Endocrine Disorders. Part I: Effect of Thyroid Hormone1 , 1963 .

[47]  B. Ray,et al.  Diabetogenic and hypoglycemic effects of human growth hormone. , 1960, Transactions of the Association of American Physicians.